Home Tags NSCLC

Tag: NSCLC

WCLC 2019: Daiichi Sankyo to Present Late-breaking Results from U3-1402 and...

The World Health Organization (WHO) estimates that lung cancer causes 1.59 million deaths globally per year. Non-small cell lung cancer (NSCLC) accounts for 80%–90%...
General Views of the 55th Annual Meeting meeting of the American Society of Clinical Oncology. Photo Courtesy: © ASCO/Nick Agro 2019.

Preliminary Phase I Data for U3-1402 Shows Manageable Safety and Reduction...

Preliminary results from the dose escalation part of the phase I study with U3-1402, an investigational and potential first-in-class HER3 targeting antibody-drug conjugate or...

Updated Results for [Fam-] Trastuzumab Deruxtecan in Patients with HER2 Mutated...

Updated phase I safety and efficacy data for trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC) being developed by Daiichi...

Phase I Study of DS-1062 in Patients with Advanced Non-Small Cell...

The first patient has been dosed in a phase I study assessing the safety and tolerability of DS-1062, an investigational trophoblast cell-surface antigen 2...

Clinical Trial with Investigational Potential First-in-class HER3-targeting Antibody-drug Conjugate

A first patient has been dosed in a phase I study evaluating the safety and tolerability of U3-1402, in patients with metastatic or unresectable...

AbbVie and Bristol-Myers Squibb Evaluate Telisotuzumab Vedotin and Nivolumab in c-Met...

A new clinical trial collaboration between AbbVie and Bristol-Myers Squibb Company will evaluate the combination of AbbVie's investigational antibody-drug conjugate telisotuzumab vedotin also known...

Sacituzumab govitecan (IMMU-132) Demonstrates Therapeutic Potential in the Treatment of Metastatic...

Two prominent cancer journals have published phase II clinical trial results with sacituzumab govitecan (IMMU-132; Immunomedics) in a total of 104 patients with lung...

Immune Checkpoint Inhibitor Nivolumab: Five-year Survival Rate in Advanced Lung Cancer

Data from a phase I clincal trial presented at the Annual Meeting of American Association for Cancer Research (AACR), beimg held April 1-5, 2017...

Mersana’s XMT-1536 Demonstrates Anti-tumor Activity in Lung Cancer Patient-Derived Xenograft Studies

Encouraging data from preclinical studies presented at the 2016 IASLC 17th World Conference on Lung Cancer, in Vienna, Austria, suggests that Mersana Therapeutics' immunoconjugate XMT-1536...

Comparison of Three Different PD-L1 Diagnostic Tests Shows a High Degree of...

Three commercially available diagnostic tests were similarly effective in measuring PD-L1 protein expression on non-small cell lung cancer (NSCLC) tumor samples, indicating that health...

FEATURED RESOURCES